Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • ID: 4340232
  • Report
  • 89 pages
  • P&S Market Research
1 of 3
Pipeline Overview

BACE is a cleaving enzyme of aspartyl protease with beta-secretase activity. It acts as a precursor of beta-amyloid (Aß) protein. In Alzheimer’s disease, the Aß protein fragments get accumulated in plaques in the brain. BACE initiates Aß production by cleaving amyloid precursor protein (APP) to generate APPß and C99, which is critical for the subsequent cleavage of C99 by gamma-secretase to release Aß1-40 and Aß1-42. Inhibition of BACE enzyme disrupts the production of toxic Aß and forms plaque and new soluble oligomers.

Alzheimer’s disease is a common type of dementia and a fatal illness. It includes memory loss and loss of other intellectual abilities, which results in serious interference with daily life. Around 60% to 80% of dementia cases turn out to be Alzheimer’s disease. It causes problems with behavior, thinking and memory. Symptoms usually develop at a slow rate and become worse with time, causing severe interference with daily routine. The efficient inhibition of BACE is expected to stop the progression of Alzheimer’s disease. BACE inhibitors as drug candidates will block Aß enzyme, which would prevent the buildup of beta-amyloid and may also help to reduce or halt Alzheimer’s disease.

Although significant progress has been witnessed in BACE inhibitor development, studies are still focused on BACE inhibitors with high potential, and reduced or no side effects. Also, even after promising growth in the development of BACE inhibitors, BACE therapeutics for Alzheimer’s disease treatment are still not available in the market due to the difficulty in the designing of BACE1 inhibitor drugs that can pass the blood-brain barrier.

As of February 2017, the BACE inhibitors pipeline comprised 15 product candidates in different stages of development.

BACE Inhibitors Pipeline Analysis

Competitive Landscape

Some of the key players developing BACE inhibitors pipeline are AstraZeneca plc, Eli Lilly & Company and Merck & Co and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
  • Market Forecast - Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Bace Inhibitors Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Route Of Administration
4.4.3 Pipeline Analysis By Company

5. Beta-Secretase (Bace) Inhibitors Pipeline Analysis By Phase (2017)
5.1 Phase Iii: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Ii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Discovery: Drug Profiles
5.5.1 Strategic Development
5.5.2 Designation
5.5.3 Grants
5.5.4 Patent
5.5.5 Technology
5.6 Inactive: Drug Profiles
5.6.1 Pre-Clinical Study
5.6.2 Pre-Clinical Results
5.6.3 Clinical Trials
5.6.4 Clinical Results
5.6.5 Strategic Development
5.6.6 Designation
5.6.7 Grants
5.6.8 Patent
5.6.9 Technology
5.7 Discontinued: Drug Profiles
5.7.1 Pre-Clinical Study
5.7.2 Pre-Clinical Results
5.7.3 Clinical Trials
5.7.4 Clinical Results
5.7.5 Strategic Development
5.7.6 Designation
5.7.7 Grants
5.7.8 Patent
5.7.9 Technology

6 Competitive Landscape
6.1 Benchmarking Of Bace Inhibitor Drug Candidates Of Key Players
6.2 Swot Analysis Of Bace Inhibitors Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Bace Inhibitors, By Company (2017)
Discontinued Bace Inhibitors Drug Candidates (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Description Of Inactive Drug Candidates
Description Of Discontinued Drug Candidates
Swot Analysis Of Bace Inhibitors Pipeline
Companies- At A Glance

List Of Figures
Research Methodology For The Bace Inhibitors Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents By Industry Participant
Breakdown Of Primary Research Respondents By Company Type
Number Of Bace Inhibitors Products Under Development (2017)
Bace Inhibitors Pipeline Split, By Route Of Administration (2017)
Benchmarking Of Bace Inhibitors Drug Candidates Of Key Players
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll